Christopher G Azzoli

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi Trastuzumab in the treatment of non-small cell lung cancer
    Christopher G Azzoli
    Department of Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Semin Oncol 29:59-65. 2002
  2. ncbi A phase 1 study of pralatrexate in combination with paclitaxel or docetaxel in patients with advanced solid tumors
    Christopher G Azzoli
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Cancer Res 13:2692-8. 2007
  3. doi Molecularly tailored adjuvant chemotherapy for resected non-small cell lung cancer: a time for excitement and equipoise
    Christopher G Azzoli
    Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, New York 10021, USA
    J Thorac Oncol 3:84-93. 2008
  4. pmc A phase II tolerability study of cisplatin plus docetaxel as adjuvant chemotherapy for resected non-small cell lung cancer
    Christopher G Azzoli
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, New York 10021, USA
    J Thorac Oncol 2:638-44. 2007
  5. doi Pralatrexate with vitamin supplementation in patients with previously treated, advanced non-small cell lung cancer: safety and efficacy in a phase 1 trial
    Christopher G Azzoli
    Memorial Sloan Kettering Cancer Center, New York City, New York, USA
    J Thorac Oncol 6:1915-22. 2011
  6. ncbi Can adjuvant chemotherapy improve survival in patients with early-stage, resected non-small-cell lung cancer?
    Christopher G Azzoli
    Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Nat Clin Pract Oncol 2:552-3. 2005
  7. ncbi A phase I trial of perillyl alcohol in patients with advanced solid tumors
    Christopher G Azzoli
    Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer Chemother Pharmacol 51:493-8. 2003
  8. ncbi Gemcitabine-induced peripheral edema: report on 15 cases and review of the literature
    Christopher G Azzoli
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Am J Clin Oncol 26:247-51. 2003
  9. ncbi A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations
    Gregory J Riely
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York City, New York, USA
    J Thorac Oncol 6:1435-7. 2011
  10. doi Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib
    Sandra P D'Angelo
    Department of Medicine, Division of Solid Tumor Oncology, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Thorac Oncol 7:1815-22. 2012

Detail Information

Publications56

  1. ncbi Trastuzumab in the treatment of non-small cell lung cancer
    Christopher G Azzoli
    Department of Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Semin Oncol 29:59-65. 2002
    ..Whether trastuzumab will show a clear benefit for patients with NSCLC, either alone or in combination with established chemotherapy, remains to be proven in phase III testing...
  2. ncbi A phase 1 study of pralatrexate in combination with paclitaxel or docetaxel in patients with advanced solid tumors
    Christopher G Azzoli
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Cancer Res 13:2692-8. 2007
    ..This phase 1 study was designed to determine the maximum tolerated dose and toxicity of pralatrexate plus paclitaxel or docetaxel in patients with advanced cancer...
  3. doi Molecularly tailored adjuvant chemotherapy for resected non-small cell lung cancer: a time for excitement and equipoise
    Christopher G Azzoli
    Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, New York 10021, USA
    J Thorac Oncol 3:84-93. 2008
    ..This paper will review the molecular markers which are having immediate impact on treatment decisions in routine practice, and which merit further study in the next generation of adjuvant chemotherapy trials...
  4. pmc A phase II tolerability study of cisplatin plus docetaxel as adjuvant chemotherapy for resected non-small cell lung cancer
    Christopher G Azzoli
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, New York 10021, USA
    J Thorac Oncol 2:638-44. 2007
    ..We undertook this phase II study to measure postoperative drug delivery and toxicity of cisplatin plus docetaxel in patients with resected stage I-III non-small cell lung cancer...
  5. doi Pralatrexate with vitamin supplementation in patients with previously treated, advanced non-small cell lung cancer: safety and efficacy in a phase 1 trial
    Christopher G Azzoli
    Memorial Sloan Kettering Cancer Center, New York City, New York, USA
    J Thorac Oncol 6:1915-22. 2011
    ..This phase 1 study evaluated the safety of higher pralatrexate doses with vitamin supplementation to minimize toxicities...
  6. ncbi Can adjuvant chemotherapy improve survival in patients with early-stage, resected non-small-cell lung cancer?
    Christopher G Azzoli
    Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Nat Clin Pract Oncol 2:552-3. 2005
  7. ncbi A phase I trial of perillyl alcohol in patients with advanced solid tumors
    Christopher G Azzoli
    Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer Chemother Pharmacol 51:493-8. 2003
    ..This phase I trial was conducted to determine the optimal dose of perillyl alcohol...
  8. ncbi Gemcitabine-induced peripheral edema: report on 15 cases and review of the literature
    Christopher G Azzoli
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Am J Clin Oncol 26:247-51. 2003
    ..Patients predisposed to peripheral edema from some other cause may be at increased risk for developing severe peripheral edema with gemcitabine...
  9. ncbi A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations
    Gregory J Riely
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York City, New York, USA
    J Thorac Oncol 6:1435-7. 2011
    ..Salirasib prevents Ras membrane binding thereby blocking the function of all Ras isoforms. This phase II study determined the activity of salirasib in patients with advanced lung adenocarcinomas with KRAS mutations...
  10. doi Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib
    Sandra P D'Angelo
    Department of Medicine, Division of Solid Tumor Oncology, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Thorac Oncol 7:1815-22. 2012
    ..The clinical significance of these mutations in patients with resected stage I-III lung cancers is unclear...
  11. pmc Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer
    Gregory J Riely
    Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10022, USA
    J Clin Oncol 27:264-70. 2009
    ..However, preclinical data support the hypothesis that intermittent administration of erlotinib before or after chemotherapy may improve efficacy. We tested this hypothesis in patients with advanced NSCLC...
  12. ncbi Randomized phase II study of weekly docetaxel plus trastuzumab versus weekly paclitaxel plus trastuzumab in patients with previously untreated advanced nonsmall cell lung carcinoma
    Lee M Krug
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, New York 10021, USA
    Cancer 104:2149-55. 2005
    ..In the current study, the authors combined trastuzumab with weekly taxanes in an attempt to improve outcomes over standard chemotherapy in patients with advanced NSCLC...
  13. pmc Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer
    Katharine A Price
    Department of Medicine, Thoracic Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, New York City, New York, USA
    J Thorac Oncol 5:1623-9. 2010
    ..This phase II trial assessed the efficacy of the combination of gefitinib and everolimus in patients with advanced NSCLC...
  14. ncbi Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer
    Daniel T Milton
    Department of Medicine, Thoracic Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center and the Weill Medical College of Cornell University, New York, New York, USA
    Cancer 110:599-605. 2007
    ..A phase 1 study was conducted of the combination of everolimus, an mTOR inhibitor, and gefitinib to determine a daily dose of everolimus with gefitinib in patients with advanced nonsmall-cell lung cancer (NSCLC)...
  15. pmc Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations
    Yelena Y Janjigian
    Gastrointestinal Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York City, New York, USA
    J Thorac Oncol 6:569-75. 2011
    ..Whether treatment with TKI improves outcomes in patients with resected lung adenocarcinoma and EGFR mutation is unknown...
  16. doi Risk of hemoptysis in patients with resected squamous cell and other high-risk lung cancers treated with adjuvant bevacizumab
    Matthew D Hellmann
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical School, 300 East 66th Street, New York, NY 10065, USA
    Cancer Chemother Pharmacol 72:453-61. 2013
    ..The risk of hemoptysis may be eliminated in patients with resected SQCLCs. We evaluated the safety of adjuvant bevacizumab in patients with resected SQCLCs and other lung cancers at high risk of hemoptysis...
  17. ncbi A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer
    Daniel T Milton
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center and the Weill Medical College of Cornell University, New York, New York 10021, USA
    Cancer 107:1034-41. 2006
    ..The objective of this study was to determine the tolerability and efficacy of high-dose erlotinib administered on a weekly schedule to patients with advanced nonsmall cell lung cancer (NSCLC)...
  18. pmc Phase II trial of dasatinib for patients with acquired resistance to treatment with the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib or gefitinib
    Melissa L Johnson
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Thorac Oncol 6:1128-31. 2011
    ..The SRC inhibitor dasatinib demonstrates antitumor activity in gefitinib-resistant cells lines and xenografts. Dasatinib is tolerable for patients with advanced non-small cell lung cancer, and in combination with erlotinib...
  19. doi Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib
    Yelena Y Janjigian
    Gastrointestinal and Thoracic Oncology Services, Division of Solid Tumor Oncology, Department of Medicine and Radiology, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, New York 10065, USA
    Clin Cancer Res 17:2521-7. 2011
    ..To evaluate the toxicity and efficacy of cetuximab and erlotinib in patients with acquired resistance to erlotinib, we conducted this phase I/II clinical trial...
  20. pmc Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors
    Helena A Yu
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY 10065, USA
    J Thorac Oncol 8:346-51. 2013
    ..Metastasectomy is used in other cancers to manage oligometastatic disease. We hypothesized that local therapy is associated with improved outcomes in patients with EGFR-mutant lung cancers with acquired resistance to EGFR TKI...
  21. doi Reflex testing of resected stage I through III lung adenocarcinomas for EGFR and KRAS mutation: report on initial experience and clinical utility at a single center
    Sandra P D'Angelo
    Memorial Sloan Kettering Cancer Center, New York, NY 10019, USA
    J Thorac Cardiovasc Surg 141:476-80. 2011
    ....
  22. ncbi 10-propargyl-10-deazaaminopterin: an antifolate with activity in patients with previously treated non-small cell lung cancer
    Lee M Krug
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University New York, New York 10021, USA
    Clin Cancer Res 9:2072-8. 2003
    ..The recommended Phase II dose was 150 mg/m(2) i.v. every 2 weeks. Responses observed in patients with non-small cell lung cancer (NSCLC) in the Phase I trial prompted this Phase II trial...
  23. ncbi Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial
    Lee M Krug
    Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, New York 10021, USA
    Cancer 103:2128-31. 2005
    ..The authors conducted a Phase II single-institution study of imatinib in patients with recurrent SCLC whose tumor specimens expressed c-kit protein...
  24. pmc Phase II study of docetaxel and vinorelbine as adjuvant chemotherapy for resected non-small cell lung cancers
    Jamie E Chaft
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, 300 E, 66th Street, New York, NY, 10065, USA
    Cancer Chemother Pharmacol 72:931-4. 2013
    ..For cisplatin ineligible patients, there is no standard adjuvant option. We evaluated drug delivery and toxicity of docetaxel and vinorelbine in patients who could not receive cisplatin...
  25. ncbi Phase II trial of neoadjuvant bevacizumab plus chemotherapy and adjuvant bevacizumab in patients with resectable nonsquamous non-small-cell lung cancers
    Jamie E Chaft
    Department of Medicine, Division of Solid Tumor Oncology, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York 10065, USA
    J Thorac Oncol 8:1084-90. 2013
    ..Bevacizumab improves survival in patients with advanced non-small-cell lung cancer (NSCLC). This phase II clinical trial assessed the effects of the addition of bevacizumab to neoadjuvant chemotherapy in resectable nonsquamous NSCLC...
  26. doi Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancer
    M Catherine Pietanza
    Department of Medicine, Thoracic Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY, USA
    J Thorac Oncol 7:856-65. 2012
    ..We undertook an open-label, multi-institutional Phase II study to investigate the efficacy and safety of XL647 in treatment-naive non-small-cell lung cancer patients clinically enriched for the presence of EGFR mutations...
  27. pmc Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib
    Geoffrey R Oxnard
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York, USA
    Clin Cancer Res 17:6322-8. 2011
    ..To better understand these results, we studied the natural history of lung cancers which recurred despite adjuvant TKI...
  28. pmc Molecular characteristics predict clinical outcomes: prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene
    Naiyer A Rizvi
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, New York, New York 10021, USA
    Clin Cancer Res 17:3500-6. 2011
    ..To determine if tumor regression following treatment with gefitinib correlates with the presence of sensitizing mutations in epidermal growth factor receptor (EGFR)...
  29. doi Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer
    Naiyer A Rizvi
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 26:639-43. 2008
    ..We undertook this trial to determine the maximum-tolerated dose (MTD) and single-agent activity of NAB-paclitaxel administered on a weekly basis to patients with stage IV non-small-cell lung cancer (NSCLC)...
  30. pmc A phase 2 study of weekly albumin-bound paclitaxel (Abraxane®) given as a two-hour infusion
    Paul K Paik
    Department of Medicine, Thoracic Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, H1011, New York, NY 10065, USA
    Cancer Chemother Pharmacol 68:1331-7. 2011
    ..We sought to determine if the incidence and severity of peripheral neuropathy could be reduced when the infusion time is lengthened to 2-h...
  31. pmc Clinical outcomes with perioperative chemotherapy in sarcomatoid carcinomas of the lung
    Jamie E Chaft
    Department of Medicine, Division of Solid Tumor Oncology, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York 10065, USA
    J Thorac Oncol 7:1400-5. 2012
    ..We sought to determine the effect of perioperative chemotherapy in patients with completely resected sarcomatoid carcinomas of the lung...
  32. doi Use of epidermal growth factor receptor/Kirsten rat sarcoma 2 viral oncogene homolog mutation testing to define clonal relationships among multiple lung adenocarcinomas: comparison with clinical guidelines
    Nicolas Girard
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Chest 137:46-52. 2010
    ..Here, we report on seven patients in whom epidermal growth factor receptor (EGFR) and Kirsten-rat sarcoma 2 viral oncogene homolog (KRAS) tumor mutation status was used to determine clonal relationships among multiple lung lesions...
  33. pmc Screening for germline EGFR T790M mutations through lung cancer genotyping
    Geoffrey R Oxnard
    Thoracic Oncology Service and Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Thorac Oncol 7:1049-52. 2012
    ..We hypothesized that patients with lung cancers found to harbor the EGFR T790M resistance mutation before treatment, an uncommon occurrence, would be likely to carry underlying germline T790M mutations...
  34. pmc A phase I trial of SJG-136 (NSC#694501) in advanced solid tumors
    Yelena Y Janjigian
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, 1275 York Avenue, New York, NY 10065, USA
    Cancer Chemother Pharmacol 65:833-8. 2010
    ..We undertook this trial to determine the maximum-tolerated dose (MTD), toxicities and pharmacokinetic (PK) profile of SJG-136 in patients with an advanced solid tumor...
  35. doi Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma
    Jenifer L Marks
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Thorac Oncol 3:111-6. 2008
    ..Whether EGFR and KRAS mutations also have an impact on survival in patients who undergo lung resection for curative intent in the absence of targeted therapy has not been established...
  36. ncbi A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors
    Matthew G Fury
    Division of Solid Tumor Oncology, Head and Neck Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY 10021, USA
    Cancer Chemother Pharmacol 59:467-75. 2007
    ....
  37. pmc Analysis of genetic variants in never-smokers with lung cancer facilitated by an Internet-based blood collection protocol: a preliminary report
    Nicolas Girard
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Clin Cancer Res 16:755-63. 2010
    ..We hypothesized that we could use the Internet to bolster the accrual of appropriate patients...
  38. doi Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker
    M Catherine Pietanza
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, 300 East 66th Street, New York, NY 10065, USA
    Clin Cancer Res 18:1138-45. 2012
    ..This phase II study was conducted to assess the efficacy of temozolomide in patients with relapsed small cell lung cancer (SCLC)...
  39. ncbi A phase I clinical pharmacologic study of pralatrexate in combination with probenecid in adults with advanced solid tumors
    Matthew G Fury
    Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, 10021, USA
    Cancer Chemother Pharmacol 57:671-7. 2006
    ..The aim of this phase I study was to determine the maximum-tolerated dose of pralatrexate when combined with probenecid given every 2 weeks in humans...
  40. doi A case series of dose-limiting peripheral edema observed in patients treated with pemetrexed
    Sandra P D'Angelo
    Division of Solid Tumor Oncology, Thoracic Oncology Services, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, New York, USA
    J Thorac Oncol 6:624-6. 2011
    ..In the phase I and II trials, the dose-limiting toxicities of pemetrexed included neutropenia, thrombocytopenia, and fatigue. Grade 3 bilateral peripheral edema that resembled cellulitis was not commonly described...
  41. ncbi Pulmonary toxicity associated with erlotinib
    Vincent Liu
    Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Chest 132:1042-4. 2007
    ..Similar to reports in patients receiving gefitinib, those with pathologic findings of UIP on resected lung specimens or known pulmonary fibrosis may be at particular risk for erlotinib pulmonary toxicity...
  42. ncbi Targeting lethal minimal residual disease in small cell lung cancer
    Jyoti D Patel
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, NY 10021, USA
    Semin Oncol 30:79-85. 2003
    ..This review will focus on the detection of minimal residual disease as well as strategies with which to treat it, including matrix metalloproteinase inhibitors, tyrosine kinase inhibitors, and vaccine therapy...
  43. ncbi A grading system of lung adenocarcinomas based on histologic pattern is predictive of disease recurrence in stage I tumors
    Gabriel Sica
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Am J Surg Pathol 34:1155-62. 2010
    ..65 (95% confidence interval 0.57-0.73). Therefore, this scoring system provides valuable information in discriminating patients with different risk of disease-recurrence in a highly homogeneous population of patients with stage I cancer...
  44. pmc Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors
    Marie Brevet
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, United States
    Lung Cancer 73:96-102. 2011
    ..In this study, we combined a mass spectrometry genotyping assay (Sequenom) with a mutant-enriched PCR (ME-PCR) to detect EGFR mutations in free plasma DNA from patients with lung cancer...
  45. doi Recurrent non-small cell lung cancer: evaluation of CT-guided radiofrequency ablation as salvage therapy
    Helmut Schoellnast
    Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Acta Radiol 53:893-9. 2012
    ..Although several studies have evaluated the use of RFA in primary NSCLC, there is little literature on its potential application as a salvage tool...
  46. doi Chemoradiation for unresectable stage III non-small cell lung cancer
    Katharine A R Price
    Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Semin Thorac Cardiovasc Surg 20:204-9. 2008
    ..In the future, more effective, less toxic chemotherapy drugs and better radiation techniques should improve outcomes for patients with unresectable stage III non-small cell lung cancer (NSCLC)...
  47. pmc Benefits and harms of CT screening for lung cancer: a systematic review
    Peter B Bach
    Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    JAMA 307:2418-29. 2012
    ..Lung cancer is the leading cause of cancer death. Most patients are diagnosed with advanced disease, resulting in a very low 5-year survival. Screening may reduce the risk of death from lung cancer...
  48. pmc Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer
    Kevin C De Braganca
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Neurooncol 100:443-7. 2010
    ..This series suggests bevacizumab may be safe and effective for progressive brain metastases from NSCLC and deserves further study...
  49. ncbi Serum biomarkers for assessing histology and outcomes in patients with metastatic lung cancer
    Emil Lou
    Department of Medicine, Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN, USA
    Cancer Biomark 14:207-14. 2014
    ..Serum biomarkers are not in routine clinical use for diagnosis, prognosis, or treatment selection in lung cancer...
  50. pmc 2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer
    Christopher G Azzoli
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 29:3825-31. 2011
    ..This document updates one recommendation of the ASCO Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer (NSCLC) regarding switch maintenance chemotherapy...
  51. pmc 2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer
    Christopher G Azzoli
    Memorial Sloan Kettering Cancer Center, New York, NY American Society of Clinical Oncology, Alexandria, VA and National Cancer Institute, Bethesda, MD
    J Oncol Pract 8:63-6. 2012
    ..III randomized clinical trials published on maintenance chemotherapy, addressing one question from the 2009 Guideline Update on chemotherapy for stage IV NSCLC: what is the optimal duration of first-line chemotherapy for stage IV NSCLC?..
  52. ncbi Cisplatin versus carboplatin for patients with metastatic non-small-cell lung cancer--an old rivalry renewed
    Christopher G Azzoli
    J Natl Cancer Inst 99:828-9. 2007
  53. ncbi Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline
    Katherine M W Pisters
    M D Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 25:5506-18. 2007
    ..To determine the role of adjuvant chemotherapy and radiation therapy in patients with completely resected stage IA-IIIA non-small-cell lung cancer (NSCLC)...
  54. ncbi Management of patients with resectable stage IIIA (N2) NSCLC
    Christopher G Azzoli
    J Surg Oncol 94:551-2. 2006
  55. ncbi Adjuvant chemotherapy for resected non-small-cell lung cancer--ANITA takes the stage
    Christopher G Azzoli
    Lancet Oncol 7:701-3. 2006
  56. ncbi American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003
    David G Pfister
    American Society of Clinical Oncology, Cancer Policy and Clinical Affairs, 1900 Duke St, Suite 200, Alexandria, VA 22314, USA
    J Clin Oncol 22:330-53. 2004